Marinomed Signs Collaboration with Boehringer Ingelheim for Anti-Viral Nasal Spray Against Common Cold
Marinomed Biotechnologie GmbH announced that it has signed a licensing agreement with Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed’s anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia. This nasal spray is based on Marinomed’s anti-viral respiratory technology platform mavirex. Marinomed will receive an upfront payment in the million EUR range from Boehringer Ingelheim, in addition to payments upon the achievement of certain market entry milestones and royalties. Further financial details were not disclosed.
Dr. Thomas Friedrich, CFO of Marinomed, said: “This is a landmark agreement for Marinomed. We are delighted to commence a long-term collaboration with Boehringer Ingelheim, a perfect partner for the successful marketing of our innovative common cold product worldwide.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.